4 results about "Granisetron" patented technology

The present application discloses a granisetron sustained-release microsphere and a preparation method therefor. On the basis of the mass of the granisetron sustained-release microspheres being 100%, the content of granisetron or a pharmaceutically acceptable salt thereof is 3-12%, the content of a stabilizer is 1-25%, and the content of a biodegradable polymer is 65-96%. The biodegradable polymer is a poly(lactic-co-glycolic acid), and the stabilizer is a fatty acid. The granisetron sustained-release microsphere obtained by the present invention has a high drug loading capacity, a uniform particle size, a complete morphology and no adhesion, a smooth surface without obvious pores, and no risk of burst release or drug leakage, and can achieve sustained release in vitro for up to 5-7 days.

The invention discloses a granisetron sustained-release microsphere and a preparation method thereof, the granisetron sustained-release microsphere comprises 3-12% of granisetron or its pharmaceutically acceptable salt, 1-25% of a stabilizer, and 65-96% of a biodegradable polymer according to 100% of the mass of the granisetron sustained-release microsphere, and the preparation method is characterized in that the granisetron or its pharmaceutically acceptable salt accounts for 3-12% of the mass of the granisetron sustained-release microsphere; the biodegradable polymer is a polylactic acid-glycolic acid copolymer, and the stabilizer is fatty acid; the granisetron sustained-release microspheres obtained by the invention are high in drug loading capacity, uniform in granularity, complete in form, free of adhesion, smooth in surface, free of obvious holes, free of risks of burst release and drug leakage, and capable of realizing in-vitro sustained release as long as 5-7 days.

The invention discloses an application of granisetron and / or quinolinic acid in preparation of a medicine for preventing and / or treating sepsis intestinal injury, and the medicine adjusts the composition and function of intestinal flora so as to increase the content of tryptophan metabolite quinolinic acid. Quinolinic acid plays a role in prevention and / or treatment by repairing an intestinal immune barrier and regulating a tryptophan metabolic pathway. The application finds that granisetron can regulate intestinal flora and increase the content of tryptophan metabolite quinolinic acid, the quinolinic acid can repair an intestinal immune barrier and regulate a tryptophan metabolic pathway, and granisetron and the quinolinic acid can be used independently or jointly to reduce the systemic inflammation level, repair the intestinal immune barrier and improve sepsis intestinal injury. In addition, multiple key beneficial strains and key metabolites are determined and can be used for early prevention and treatment of sepsis. The application develops a new thought for preventing sepsis, is expected to reduce the onset risk by regulating intestinal flora, and has important significance in the fields of clinical treatment and disease prevention.

The invention relates to the field of medicine, in particular to a composition as well as a preparation method and application thereof. The composition provided by the invention comprises granisetron, a sustained-release carrier, a viscosity modifier and / or a surfactant. The invention provides a pre-potting injection for treating vomiting symptoms and a preparation method and application thereof.The pre-potting injection is composed of a pharmaceutical composition and a pre-potting drug delivery assembly, the pharmaceutical composition comprises granisetron, a sustained-release carrier, a viscosity modifier and / or a surfactant, the granisetron, the sustained-release carrier, the viscosity modifier and / or the surfactant are matched with the pre-potting drug delivery assembly for drug delivery, and the sustained-release carrier and the viscosity modifier are matched with the pre-potting drug delivery assembly for drug delivery. Therefore, the preparation which is free of burst release, long in acting and more convenient to use clinically is obtained.